Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PSNLNASDAQ:TEM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePSNLPersonalis$4.16+7.8%$3.62$1.14▼$7.20$367.36M1.89980,331 shs960,158 shsTEMTempus AI$57.06+10.0%$48.11$22.89▼$91.45$9.83BN/A5.74 million shs12.30 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePSNLPersonalis+7.77%+8.33%+16.85%-20.31%+168.39%TEMTempus AI+10.05%+7.86%+14.37%-0.58%+5,705,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPSNLPersonalis3.6624 of 5 stars3.51.00.04.21.91.70.6TEMTempus AI1.5244 of 5 stars2.32.00.00.02.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePSNLPersonalis 3.00Buy$7.8087.50% UpsideTEMTempus AI 2.54Moderate Buy$61.087.05% UpsideCurrent Analyst Ratings BreakdownLatest PSNL and TEM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2025TEMTempus AINeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.004/21/2025TEMTempus AIBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$60.004/10/2025PSNLPersonalisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/10/2025TEMTempus AINeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.003/17/2025PSNLPersonalisCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.003/6/2025TEMTempus AIMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$50.00 ➝ $60.003/4/2025TEMTempus AIPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$70.00 ➝ $55.003/3/2025TEMTempus AIBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$54.00 ➝ $60.002/28/2025PSNLPersonalisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.002/28/2025PSNLPersonalisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.25 ➝ $7.002/26/2025TEMTempus AIWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPSNLPersonalis$84.61M4.34N/AN/A$2.64 per share1.58TEMTempus AI$693.40M14.17N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePSNLPersonalis-$108.30M-$1.37N/AN/AN/A-104.52%-66.07%-41.34%5/6/2025 (Estimated)TEMTempus AI-$289.81MN/A0.00N/AN/AN/AN/A-111.38%5/6/2025 (Estimated)Latest PSNL and TEM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025PSNLPersonalis-$0.23N/AN/AN/A$17.41 millionN/A5/6/2025Q1 2025TEMTempus AI-$0.27N/AN/AN/A$248.13 millionN/A2/27/2025Q4 2024PSNLPersonalis-$0.32-$0.23+$0.09-$0.23$15.48 million$16.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPSNLPersonalisN/AN/AN/AN/AN/ATEMTempus AIN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPSNLPersonalisN/A4.684.44TEMTempus AI8.172.692.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPSNLPersonalis61.91%TEMTempus AI24.22%Insider OwnershipCompanyInsider OwnershipPSNLPersonalis3.80%TEMTempus AI27.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePSNLPersonalis40088.31 million67.75 millionOptionableTEMTempus AI2,300172.21 millionN/AN/APSNL and TEM HeadlinesRecent News About These CompaniesTempus exec-founded Pathos AI launched a $400M funding round. It's already filling up.May 2 at 6:21 PM | chicagobusiness.comThink It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.May 2 at 8:58 AM | fool.comTempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and EnrollmentMay 2 at 5:52 AM | tmcnet.comTempus selects TIME Network for Phase I clinical trialsMay 2 at 5:52 AM | finance.yahoo.comNebula Research & Development LLC Takes Position in Tempus AI, Inc. (NASDAQ:TEM)May 2 at 4:56 AM | marketbeat.comTempus AI (TEM) to Release Earnings on TuesdayMay 1 at 12:45 PM | marketbeat.comTempus AI (NASDAQ:TEM) Stock Price Up 6.1% - What's Next?April 30 at 2:11 PM | marketbeat.comEnvestnet Asset Management Inc. Increases Stock Position in Tempus AI, Inc. (NASDAQ:TEM)April 30 at 3:24 AM | marketbeat.comTempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy SelectionApril 29, 2025 | finance.yahoo.comMission Creek Capital Partners Inc. Buys New Position in Tempus AI, Inc. (NASDAQ:TEM)April 29, 2025 | marketbeat.com13,526 Shares in Tempus AI, Inc. (NASDAQ:TEM) Acquired by Oxford Asset Management LLPApril 29, 2025 | marketbeat.comGilder Gagnon Howe & Co. LLC Invests $775,000 in Tempus AI, Inc. (NASDAQ:TEM)April 29, 2025 | marketbeat.comRaymond James Financial Inc. Buys Shares of 111,288 Tempus AI, Inc. (NASDAQ:TEM)April 29, 2025 | marketbeat.comTempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings?April 28, 2025 | zacks.comTempus Introduces Loop, an AI-Powered Target Discovery and Validation PlatformApril 28, 2025 | finance.yahoo.comHBK Investments L P Invests $5.06 Million in Tempus AI, Inc. (NASDAQ:TEM)April 27, 2025 | marketbeat.comWhy Tempus AI Inc. (TEM) Soared Last WeekApril 26, 2025 | msn.comTempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025April 25, 2025 | finance.yahoo.comAstraZeneca joins Tempus, Pathos in cancer AI projectApril 24, 2025 | pharmaphorum.com5TEM : Beyond The Numbers: 9 Analysts Discuss Tempus AI StockApril 24, 2025 | benzinga.comTempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?April 24, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeat3 Hot New IPOs Defying the 2025 Market SlumpBy Leo Miller | April 14, 2025View 3 Hot New IPOs Defying the 2025 Market SlumpPSNL and TEM Company DescriptionsPersonalis NASDAQ:PSNL$4.16 +0.30 (+7.77%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$4.14 -0.02 (-0.48%) As of 05/2/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.Tempus AI NASDAQ:TEM$57.06 +5.21 (+10.05%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$57.16 +0.09 (+0.17%) As of 05/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/28 - 05/02 Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Why Spotify Stock Still Has Room to Run in 2025 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
